Randomized Controlled Trial of mirtazapine vs lithium as augmentation after SSRI/SNRI failure.

Randomized Controlled Trial of mirtazapine vs lithium as augmentation after SSRI/SNRI failure. - Mirtazapin Effectiveness for Treatment Resistant depressION (METRION)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008451

Enrollment

120

Registered

2012-07-17

Start date

2012-07-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

Flexible dosage of mirtazapine(15-45mg) for 12 weeks. lexible dosage of lithium(100-1200mg) for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient (25 or older) with depression defined by DSN-IV whose HAM-D score are at least 18 . Patient who took stable SSRI or SNRI therapy for 4 weeks or more.

Exclusion criteria

Exclusion criteria: Subjects with clinically significant unstable medical illness, pregnancy, a principal psychiatric diagnosis other than major depression, a history of substance abuse or dependence active within the previous 6 months, and electroconvulsive therapy within the previous 6 months were excluded. Subjects with axis I disorder other than major depressive disorder and personality disorder was also excluded.

Design outcomes

Primary

Measure	Time frame
HAM-D change after 3 months of treatment. Remission rate.	—

Secondary

Measure	Time frame
Adverse effect	—

Countries

Japan

Contacts

Public ContactMASAKI KATO

1972 Department of Neuropsychiatry

katom@takii.kmu.ac.jp06-6992-1001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026